Dana Investment Advisors Inc. Buys Shares of 74,657 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Dana Investment Advisors Inc. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 74,657 shares of the company's stock, valued at approximately $808,000. Dana Investment Advisors Inc. owned approximately 0.13% of Olema Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Olema Pharmaceuticals by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,562 shares of the company's stock valued at $120,000 after buying an additional 4,221 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Olema Pharmaceuticals in the second quarter worth about $145,000. Entropy Technologies LP acquired a new stake in Olema Pharmaceuticals in the first quarter worth about $161,000. EntryPoint Capital LLC increased its position in Olema Pharmaceuticals by 949.9% in the first quarter. EntryPoint Capital LLC now owns 14,530 shares of the company's stock worth $164,000 after purchasing an additional 13,146 shares during the period. Finally, Ensign Peak Advisors Inc increased its position in Olema Pharmaceuticals by 6.1% in the second quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company's stock worth $161,000 after purchasing an additional 850 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 5,000 shares of the firm's stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $12.26, for a total transaction of $61,300.00. Following the transaction, the director now owns 756,283 shares in the company, valued at approximately $9,272,029.58. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $12.26, for a total transaction of $61,300.00. Following the transaction, the director now owns 756,283 shares in the company, valued at $9,272,029.58. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Biocapital Advisors L. Paradigm sold 2,400,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $14.91, for a total value of $35,784,000.00. Following the transaction, the insider now owns 783,118 shares in the company, valued at $11,676,289.38. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,409,066 shares of company stock worth $35,908,648. Insiders own 19.40% of the company's stock.

Olema Pharmaceuticals Stock Performance

OLMA traded up $0.04 during midday trading on Friday, reaching $11.60. 202,456 shares of the company were exchanged, compared to its average volume of 791,383. Olema Pharmaceuticals, Inc. has a one year low of $8.51 and a one year high of $17.79. The stock has a market capitalization of $648.83 million, a P/E ratio of -5.74 and a beta of 2.02. The stock's 50-day simple moving average is $12.66 and its 200 day simple moving average is $11.76.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.54). On average, research analysts anticipate that Olema Pharmaceuticals, Inc. will post -1.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on OLMA. Oppenheimer reiterated an "outperform" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered their price objective on Olema Pharmaceuticals from $33.00 to $31.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $27.00.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.